bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P6-09-09: Analysis of serial circulating tumor cell count during neoadjuvant systemic therapy in breast cancer patients
Authors: Gwark S-C , Kim J , Kim YH , Kim MS , Park JY , Lee SB , Sohn G , Chung IY , Ko BS , Kim HJ , Lee JW , Son BH , Ahn SH 
Published: May 2019

Abstract
Background: We aimed to evaluate the clinical implication of circulating tumor cell (CTC) counts in correlation with prognosis and radiologic/pathologic response to therapy in locally advanced breast cancer patients undergoing preoperative systemic therapy.
Methods: From Feb 2014 to May 2017, 207 patients without distant metastasis were prospectively enrolled from AMC. CTC counts were analyzed before-during-after the therapy. CTC isolation was performed using a SMART BIOPSY™ SYSTEM Isolation kit (Cytogen, Inc., Seoul, Korea). Recurrence-free and overall survival was analyzed according to CTC counts.
Result: The mean follow-up period was 22.46 months and mean age was 46.48 years. One or more CTC was identified in 132 of 203 patients(65.0%) before NST, in 135 of 186 patients(72.0%) during NST and 103 of 171 patients(60.2%) after NST. Initial tumor burden at diagnosis -tumor size, lymph node metastasis- was not correlated with CTC positivity. Overall, CTC count ((≥1 CTC, ≥2 CTCs, and ≥5 CTCs) was not correlated with response to therapy. Using RECIST criteria, 86.5% (179/204) were responders (complete, partial response, CR/PR) and 12.1% (25/204) were non-responders (stable, progressive disease, SD/PD). 14.5% (30/207) showed a pathologic complete response (pCR), yet no association was found between CTC count/changes and radiologic/pathologic response to therapy. Also, CTC count was not correlated with prognosis among the whole population. However, HR+ tumors, CTC detection before NST was significantly associated with treatment response by RECIST criteria (responder vs. non-responder) (p=0.003, p=0.017 and p=0.023, respectively).
Conclusions: Our findings support limited value of CTC count for locally advanced breast cancers undergoing neoadjuvant systemic therapy.
Citation Format: Gwark S-C, Kim J, Kim YH, Kim MS, Park JY, Lee SB, Sohn G, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH. Analysis of serial circulating tumor cell count during neoadjuvant systemic therapy in breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-09-09.
Abstract P6-12-01: Withdrawn
Authors: Palliyaguru DL , Chartoumpekis DV , Skoko JJ , Wendell SG , Woodcock SR , Wakabayashi N , Yagishita Y , Oesterreich S , Michalopoulos GK , Kensler TW 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Palliyaguru DL, Chartoumpekis DV, Skoko JJ, Wendell SG, Woodcock SR, Wakabayashi N, Yagishita Y, Oesterreich S, Michalopoulos GK, Kensler TW. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-12-01.
Abstract P6-13-03: Not presented
Authors: Glaspy J , Tang T , Rutty D , Yan X , Bondarenko I , Burdaeva O 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Glaspy J, Tang T, Rutty D, Yan X, Bondarenko I, Burdaeva O. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-13-03.
Abstract P6-13-04: Estrogen-alone based hormone replacement therapy (HRT) reduces breast cancer (BrCa) incidence and mortality whereas estrogen plus progestin Provera based HRT increases both BrCa incidence and BrCa mortality: A comparative analysis of Women's Health Initiative trials
Authors: Ragaz J , Qian H , Wong H , Wilson KS , Shakeraneh S , Spinelli JJ 
Published: May 2019

Abstract
OBJECTIVE: To quantitate breast cancer incidence (BrCa-I) and mortality (BrCa-M) outcome differences between the two Women's Health Initiative (WHI) HRT trials,1,2 the ratio of hazards was calculated for estrogen-alone based hormone replacement therapy (E-HRT) vs. placebo (P), and E + progestin Provera (ProgProv) combination HRT vs. P trials.
METHODS: Hazard ratios (HR) of BrCa-I and BrCa-M and 95% confidence intervals (CI) were obtained from both WHI HRT trials. Subsequently, to compare BrCa outcomes between E-HRT vs. E + ProgProv, the ratios of HRs between the trials (HR1/HR2) were estimated separately for i. BrCa-I all women, ii. BrCa-I low Gail score (Gail score &lt;1.75*), and iii. BrCa-M. The 95% CI was derived through logarithmic transformation of the 95% CI originally reported.
RESULTS:
Outcome Comparison, the two WHI HRT randomized trials. Ratio of Hazards, BrCa Incidence and BrCa mortality E-HRT vs. P, HR1 (95% CI)E-HRT + ProgProv vs. P, HR2 (95% CI)HR1/HR2 (95% CI)pBrCa-I All Woman10.77 (0.62-0.95)1.25 (1.07-1.46)0.62 (0.47-0.80)0.0004BrCa-I Low Gail Score* (Gail score &lt;1.75)10.65 (0.50-0.86)1.24 (1.01-1.51)0.53 (0.38-0.74)0.0002BrCa-M20.55 (0.33-0.92)1.44 (0.97-2.15)0.38 (0.20-0.75)0.004*Gail score &lt;1.75; HRs calculated from Reference 1, Figure 3
CONCLUSIONS: Our calculations show that the different outcomes between the two WHI HRT trials, estimated as ratio of hazards, are highly significant on statistical basis, both for BrCa incidence and for BrCa mortality. These findings highlight the potential carcinogenic impact of ProgProv and the major public health benefits of HRT based on E alone.
REFERENCES:
1. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. The Lancet Oncology 2012;13:476-86.
2. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318:927-38.
Citation Format: Ragaz J, Qian H, Wong H, Wilson KS, Shakeraneh S, Spinelli JJ. Estrogen-alone based hormone replacement therapy (HRT) reduces breast cancer (BrCa) incidence and mortality whereas estrogen plus progestin Provera based HRT increases both BrCa incidence and BrCa mortality: A comparative analysis of Women's Health Initiative trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-13-04.
Abstract P6-14-05: Withdrawn
Authors: Esser MR , Rowe JJ , McCann ML , Nicholas-Alexander M , Helck EP , Lewis SM 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Esser MR, Rowe JJ, McCann ML, Nicholas-Alexander M, Helck EP, Lewis SM. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-14-05.
Abstract P6-17-01: Withdrawn
Authors: Tolaney SM , Wardley AM , Zambelli S , Hilton JF , Troso-Sandoval TA , Ricci F , Im S-A , Kim S-B , Johnston SR , Chan A , Goel S , Catron K , Yang Z , Gainford C , André F 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im S-A, Kim S-B, Johnston SR, Chan A, Goel S, Catron K, Yang Z, Gainford C, André F. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-01.
Abstract P6-17-16: Efficacy and safety of shorter duration of adjuvant trastuzumab for patients with HER2 positive early breast cancer: A meta-analysis of randomized controlled trials
Authors: Li J , Wang G , Wu Q , Chen C , Tu Y , Yao F , Wei W , Sun S , Santa-Maria CA , Geng P 
Published: May 2019

Abstract
Background: Trastuzumab has been shown to be able to improve disease free survival(DFS) and overall survival(OS) in HER2-positive breast cancer patients. Adjuvant trastuzumab is empirically recommended for 1 year as a standard regimen. However, several studies claimed that shorter duration of adjuvant trastuzumab is non-inferior to 12 months treatment with reduced cardiac toxicities and costs.
Methods: PubMed, EMBASE, Cochrane Library, Google scholar Web, ISI Web of Science, BIOSIS and CNKI, and major conference abstracts were searched systematically in June 2018 to identify eligible non-inferiority studies comparing the intervention outcomes of adjuvant trastuzumab in chemotherapy for women with HER-2 positive breast cancer between short-term and 1-year treatments. Hazard-Ratios(HR) and corresponding 95% Confidence Intervals(CI) were calculated to compare OS and DFS of trastuzumab between short-term and long-term treatments. Pooled data of Odds-Ratio was analyzed for cardiac toxicities.
Results: 5 articles were finally eligible in the study. Totally, there were 11,376 women with HER-2 positive early breast cancer, with 5,684 in short-term group and 5,692 in the 1-year group. We found a distinct difference of DFS (HR=1.19, 95% CI=1.08-1.30) and OS (HR=1.22, 95% CI=1.07-1.39) between short-term and 12 months trastuzumab in the total analysis, which demonstrated short-term treatment exhibited a worsening trend on DFS and OS. Subgroup analysis was performed based on estrogen receptor (ER) and lymph node status, and no statistical interaction could be found(p=0.12, 0.52, respectively). The two groups with different duration of trastuzumab treatment displayed statistically significant difference for cardiotoxicities, which favored shorter duration(OR=0.54, 95% CI=0.38-0.77).
Conclusions: 1-year adjuvant trastuzumab remains the standard strategy for HER2 positive early breast cancer, however, a concomitant higher risk of associated cardiac adverse effects should not be ignored.
Citation Format: Li J, Wang G, Wu Q, Chen C, Tu Y, Yao F, Wei W, Sun S, Santa-Maria CA, Geng P. Efficacy and safety of shorter duration of adjuvant trastuzumab for patients with HER2 positive early breast cancer: A meta-analysis of randomized controlled trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-16.
Abstract P6-17-20: Withdrawn
Authors: Junttila TT , Ellerman D , Lombana N , Hristopoulos M , Clark R , Li J , Vij R , Koerber JT , Johnston J , Shelton A , Mai E , Gadkar K , Lo AA , Totpal K , Prell R , Lee G , Spiess C , Slaga D 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Junttila TT, Ellerman D, Lombana N, Hristopoulos M, Clark R, Li J, Vij R, Koerber JT, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Totpal K, Prell R, Lee G, Spiess C, Slaga D. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-20.
Abstract P6-17-29: Withdrawn
Authors: Veitch ZW , Bedard P , Tang PA , Conway JL , Ribnikar D , Albaba H , King K , Lupichuk S , Cescon D 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Veitch ZW, Bedard P, Tang PA, Conway JL, Ribnikar D, Albaba H, King K, Lupichuk S, Cescon D. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-29.
Abstract P6-17-30: Changes in patient, tumor, and treatment characteristics over time in first-line trastuzumab plus taxane (paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer trials
Authors: Badovinac Crnjevic T , Restuccia E , Michielin F , Eng-Wong J , Nüesch E 
Published: May 2019

Abstract
Background:
A retrospective analysis showed improved progression-free survival and consistent underestimation of trastuzumab (H) + taxane (T) efficacy assumptions in first-line (1L) human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) trials over time (ISCB 2016). We evaluated changes in baseline and treatment characteristics and the safety profile of H+T in 1L HER2-positive MBC trials conducted during 1995–2015.
Methods:
Trial-level data on patient, tumor, and treatment characteristics and safety profiles in H+T arms of 15 randomized trials were extracted from published data and clinical study reports. Characteristic and safety profile changes over time were explored by weighted regression; relevance was assessed by F-test.
Results:
Patient and tumor characteristics were generally stable over time. We observed relevant changes in types of adjuvant therapy used. Serious adverse events (SAEs) and study withdrawals due to Aes decreased over time; rates of treatment discontinuation due to Aes increased.
No. of trials (patients)Difference in patients with characteristic per 5 years, % (95% CI)P valueBaseline characteristics Median age15 (2895)0.5 (0.1, 0.9)*.28ECOG status 012 (2472)0.2 (-1.1, 1.6).87Hormone receptor-positive11 (2124)1.3 (-1.1, 3.6).61HER2 IHC 3+8 (1657)5.8 (3.0, 8.6).08Visceral disease10 (1970)0.5 (-2.5, 3.6).86Adjuvant therapy Hormonal therapy11 (2194)-10.1 (-12.4, -7.8).002Radiotherapy9 (2010)-4.2 -5.8, -2.6).035HER2-targeted therapy9 (2176)20.2 (13.0, 27.4).026Chemotherapy15 (2893)-7.0 (-9.2, -4.7).008Safety Grade 3+ AE6 (1342)-15.4 (-28.4, -2.5).30SAE7 (1462)-12.6 (-15.4, -9.8).006Study withdrawal due to AE8 (1525)-6.8 (-9.0, -4.5).023Treatment discontinuation due to AE6 (1370)11.5 (6.7, 16.3).075*Years (95% CI). AE, adverse events; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; SAE, serious adverse events.
Conclusions:
In 1L HER2-positive MBC trials, the percentage of patients who received adjuvant chemo-, hormonal, and radio-therapy decreased from 1995 to 2015. These changes in treatment patterns suggest a shift towards a higher percentage of patients with de novo metastatic vs recurrent disease in 1L MBC trials over time. Adjuvant H use increased following approval in 2005 as expected. While SAEs decreased over time, no firm conclusions on safety management can be made.
Citation Format: Badovinac Crnjevic T, Restuccia E, Michielin F, Eng-Wong J, Nüesch E. Changes in patient, tumor, and treatment characteristics over time in first-line trastuzumab plus taxane (paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-30.
Abstract P6-17-32: Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
Authors: Duhoux FP , Dufour V , van Maanen A , Berliere M , Taylor D , Canon J-L 
Published: May 2019

Abstract
Background Trastuzumab emtansine (T-DM1) is a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) receptors, conjugated with a cytotoxic component (a microtubule inhibitor). It is indicated as second-line treatment for HER2-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy.
In HER2-negative metastatic breast cancer, progression-free survival (PFS) declines with each line of therapy, while patients with HER2-positive disease receive the most lines of chemotherapy and the longest duration for every line. We wished to investigate whether the line of treatment in which T-DM1 is administered has an impact on PFS. We also wished to explore whether prior treatment with capecitabine / lapatinib or pertuzumab had an impact on PFS, as none of the patients included in the registration trial had received these treatments before their inclusion in the trial.
Methods This is a multicenter retrospective study performed in 3 Belgian institutions. All patients received T-DM1 for HER2 positive metastatic or unresectable locally advanced breast cancer. The primary outcome was PFS with T-DM1, defined as the period between the first administration of T-DM1 and the first radiological or clinical assessment demonstrating progression of the disease.
Results We included 51 patients. One patient had to be excluded from the analyses because she no longer had HER positive disease. The median PFS was 9.01 months. The line of treatment in which T-DM1 was administered had no influence on PFS (hazard ratio 0.976, CI95 0.835-1.142).
There was no statistically significant difference in PFS between patients who had not received capecitabine / lapatinib before T-DM1 and those who had (9.11 vs 8.91 months, p-value 0.466).
Median PFS was 10.07 months when T-DM1 was administered prior to pertuzumab, and 5 months when administered after pertuzumab. Patients who received pertuzumab before T-DM1 thus tended to exhibit a shorter PFS. However, this difference is not statistically significant (p-value 0.096).
Conclusions Unlike with conventional chemotherapy, the line of treatment in which T-DM1 is administered does not influence PFS in metastatic breast cancer patients.
Citation Format: Duhoux FP, Dufour V, van Maanen A, Berliere M, Taylor D, Canon J-L. Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-32.
Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)
Authors: Lux MP , Hartkopf AD , Huober J , Volz B , Taran F-A , Overkamp F , Hadji P , Tesch H , Haeberle L , Ettl J , Lueftner DI , Wallwiener M , Müller V , Beckmann MW , Belleville E , Wimberger P , Hielscher C , Geberth M , Lermann J , Abenhardt W , Kurbacher C , Wuerstlein R , Thomssen C , Untch M , Fasching PA , Janni W , Fehm TN , Wallwiener D , Brucker SY , Schneeweiss A , Kolberg H-C 
Published: May 2019

Abstract
Purpose:
This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer (MBC). Specifically, it describes the therapy patterns of treatments with trastuzumab (TZM), pertuzumab+trastuzumab (PTZ/TZM), lapatinib (LAP) and trastuzumab emtansine (T-DM1).
Methods:
The PRAEGNANT study is a real-time, real-world registry for patients with MBC. Patients can be registered for PRAEGNANT at any time during the course of their metastatic disease and are followed up until death. All therapy lines are documented. This analysis presents the utilization of anti-HER2 therapies as well as therapy sequences.
Results:
Of 1936 patients within PRAEGNANT at the time of database closure 451 were HER2 positive (23.3%). Within the analysis set (417 patients after an unilateral breast cancer diagnosis), of which 53% were included in PRAEGNANT in the 1stline setting, 241 were treated with TZM (58%), 237 with PTZ (57%), 85 with LAP (20%) and 125 with T-DM1 (30%) during the course of their therapies. The sequence PTZ/TZMàT-DM1 was given to 51 patients (12%). Worse ECOG, negative hormone receptor status, and visceral or brain metastases were associated with a more frequent use of this therapy sequence. Most patients received T-DM1 after a therapy with pertuzumab.
Conclusions:
Both novel therapies (PTZ/TZM and T-DM1) are utilized in a high proportion of HER2 positive breast cancer patients. As most patients receive T-DM1 after pertuzumab real world data might help to understand whether this sequence has similar efficacy like in the approval study.
Citation Format: Lux MP, Hartkopf AD, Huober J, Volz B, Taran F-A, Overkamp F, Hadji P, Tesch H, Haeberle L, Ettl J, Lueftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg H-C. Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-37.
Abstract P6-17-39: BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer
Authors: Tang W , Deng X , Ou Z , Gan J , Dong Q , Tan B , Lu L , Chen B , Bao C , Li S , Thomas B , Yu J-C 
Published: May 2019

Abstract
Overexpression of HER2 occurs in approximately 20% of breast cancers and is associated with shortened survival. Trastuzumab emtansine (T-DM1), an anti-HER2 ADC, has shown efficacy in HER2-positive breast cancer patients and was approved by the FDA and EMA for advanced HER2-positive breast cancer. However T-DM1 causes grade 3 and 4 thrombocytopenia in up to 14.5% of patients as its major toxicity. The thrombocytopenia is likely caused by one of T-DM1's catabolites and payload, DM1, indicating T-DM1's linker can be cleaved. Here we adopted a novel noncleavable linker and created an anti-HER2 ADC, BAT8001, which is expected be efficacious in HER2-positive breast cancer and have a better side effect profile relative to T-DM1 due to the stability of BAT8001's noncleavable linker. BAT8001 is internalized in HER2-positive cancer cells. It inhibits proliferation of HER2-positive tumor cells with IC50s of ˜0.1 nM, similar to the potency of T-DM1. BAT8001 also induces apoptosis in HER2-positive cancer cells. In both cell-line and patient-derived mouse xenograft (PDX) models, BAT8001 demonstrates strong inhibition activity on tumor growth. For example, in a cell-line model of breast cancer (BT474), BAT8001 demonstrates potent activity with complete responses in all animals tested at the 15mg/kg dose level. Pharmacokinetics studies in monkey reveals BAT8001 has similar Cmax, AUC, and t1/2 as T-DM1. The major catabolite of BAT8001 is the Cys-linker-payload containing product. No free payload is observed. This compares favorably with T-DM1 where free DM1, T-DM1's payload, is one of the major catabolites. In a multiple dose toxicity study, BAT8001 had a NOAEL of 15 mg/kg versus 10 mg/kg for T-DM1. BAT8001 exhibits similar potency to T-DM1 on inhibiting HER2-positive cell proliferation and tumor growth, yet demonstrates better multiple dose toxicity than T-DM1. The improved toxicity profile of BAT8001 suggests that the novel noncleavable linker utilized in BAT8001 is more stable than the linker utilized in T-DM1. BAT8001 is very efficacious in cell-line xenograft models of breast cancer. The preclinical profile of BAT8001 warrants further development for the treatment of breast cancer and other HER2-positive cancers.
Citation Format: Tang W, Deng X, Ou Z, Gan J, Dong Q, Tan B, Lu L, Chen B, Bao C, Li S, Thomas B, Yu J-C. BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-39.